Extraction of amphetamine and methamphetamine in urine was investigated using Cerex Polycrom Clin II solid-phase extraction columns and the Speedisk 48 Pressure Processor as a replacement for our llquid-liquid procedure. Linearity for urine standards extracted with the Cerex.Speedisk method ranged from 50 ng/mL for methamphetamine and from 150 ng/mL for amphetamine to 10,000 ng/mL for both. The mean recovery at the 500-ng/mL cutoff for three different lots of columns was 96.4% for AMP and 95.7% for MET. The mean of the within-run means for three batches was 495.4 ng/mL with a coefficient of variation (CV) of 1.2% or less for amphetamine and 496.4 ng/mL for methamphetamine with a CV of 1.7% or less. Thirty.six specimens containing amphetamine and the same number for methamphetamine were analyzed by both the Cerex-Speedisk and liquid-liquid methods. The correlation for specimens containing amphetamine gave an r 2 of 0.9986 with a slope of 0.99; for methamphetamine, the r 2 was 0.9997 with a slope of 0.98. The Cerex-Speedisk method cut extraction time in half, was less costly, and greatly reduced the volume of hazardous waste.
Introduction
Amphetamine (AMP) and methamphetamine (MET) abuse is increasing in the civilian and military population. Because current screening methodologies cross-react with various sympathomimetic amines multiple confirmation procedures may be necessary to determine the exact drug and in the case of MET the percentage of d-isomer. The increased confirmation workload involved in testing AMP-positive specimens places a significant burden on high-volume laboratories to meet customer turn around time demands yet process specimens in the a cost sodium hydroxide, and sulfuric acid (Mallinckrodt Baker, Inc., Paris, KY); acetic acid (E.M. Science, Gibbstown, NJ); heptafluorobutyric anhydride and sodium metaperiodate (Spectrum Quality Products, Inc., New Brunswick, NJ); sodium phosphate monobasic and sodium phosphate dibasic (Fisher Scientific, Fair Lawn, N J); and sodium azide (Sigma-Aldrich Co, Milwaukee, WI). Cerex-Polycrom Clin II columns were purchased from SPEware Corporation (San Pedro, CA). The d-isomer analysis used TPC ((S)-(-)-N-trifluoroacetyl prolylchloride), 0.1M in chloroform, and triethylamine (Aldrich, St. Louis, MO).
Extraction apparatus
The Speedisk 48 Pressure Processor was purchased from SPEware Corporation (San Pedro, CA). Autosampler vials used to collect eluate were purchased from National Scientific (Rochester, NY). A Reacti-Vap III Evaporator coupled to a Reacti-Therm III Heating Module from Pierce (Rockford, IL) was used for solvent and derivatizing reagent evaporation. Incubation was carried out using a Thermolyne Dri-Bath (Barnstead Thermolyne, DuBuque, IA). An Eberbach Reciprocal Shaker (Eberbach, Ann Arbor, MI) was used for mixing samples in the liquid-liquid extraction procedure.
Standards and controls
Standards were obtained as follows: d-amphetamine sulfate, lot 359 (Robinson Laboratory, San Francisco, CA); amphetamine-d6, lot 3699-N (C/D/N Isotopes, Inc., Pointe-Claire, QC, Canada); methamphetamine hydrochloride, lot DE1080 (Arenol Chemical Corp., Somerville, NJ); methamphetamine-d9, lot PSOFF-158 (Cambridge Isotope Laboratories, Inc., Andover, MA) and lot 30902-55C (Cerilliant, Austin, TX ); (_+)-phenylpropanolamine, lot 75F0551, (-)-ephedrine, lot 105H3677, and (+)-~-ephedrine (d-pseudoephedrine), lot 96F05311 (Sigma Chemical Co., St. Louis, MO). Stock standards of AMP and MET were prepared in methanol at concentrations of I mg/mL and 5000 ng/mL each. Urine-based standards and controls that contained both AMP and MET were prepared by spiking negative pooled human urine that contained 1 g/L sodium azide with methanol-based standards of AMP and MET to the desired concentration. The urine-based standards and controls were stored at 4~ + 2~ and were stable over the duration of use (approximately one year). Internal standard containing AMP-d6 and MET-d9 was prepared in methanol.
Processing of specimen batches
Extraction specimens were processed in batches consisting of a calibration standard containing AMP and MET each at 500 ng/mL, quality control samples (QCs) of AMP and MET at 750 ng/mL (high) and 200 ng/mL (low) each, a negative QC and eight or more specimens. Internal standard concentration was 500 ng/mL each of AMP-d6 and MET-d9 for all batches. Because the Speedisk 48 Pressure Processor sample rack is arranged in 4 rows of 12 for the simultaneous processing of 48 samples, we processed batches of 12 specimens including the calibrator and QCs. Larger batches were handled by using two rows in the rack. Specimens analyzed for MET d-isomer were processed in batches consisting of the following quality control specimens, plus six discarded service member specimens: a 50:50 d/l isomer ratio (retention time calibrator), 100% lisomer, 100% d-isomer, 50:50 d/l isomer ratio, and a negative specimen. Internal standard concentration was 1000 ng/mL for each specimen.
Cerex-Speedisk extraction procedure
The internal standard (0.200 mL of 0.005 mg/mL AMP-d6/ 0.005 mg/mL MET-d9 in methanol) was added to each 2-mL specimen contained in a 16 x 125-mm tube. Next 0.4 mL of 40% (w/v) potassium phosphate (pH 9) were added and the specimens were vortex mixed briefly. Next 0.4 mL of a 0.35M sodium metaperiodate solution were added, the specimens were vortex mixed, and allowed to stand at room temperature for a total of 10 min including centrifugation for 3-5 min. The supernatant was decanted into Cerex Polycrom Clin II (3 mL, 35 rag) columns, and each column was placed into the rack of the Speedisk 48 Pressure Processor. Using nitrogen pressure (2--4 psi), the liquid was passed through the columns. The columns were then washed with 2 mL water followed by 2 mL 0.1N acetic acid, I mL methanol and, finally, i mL ethyl acetate prior to drying for 2 rain at 25 psi. Elution was carried out by the addition of 0.8 mL of freshly prepared 2% ammonium hydroxide in ethyl acetate at 1-2 psi or by gravity followed by a pressure pulse. The eluate was collected in 2-mL autosampler vials and evaporated under nitrogen to a volume of approximately 0.1 mL. Specimens were not taken to dryness to avoid evaporative losses, at either ambient temperature or up to 37~ After concentrating, derivatization was carried out by adding 0.05 mL heptafluorobutyric anhydride (HFBA). The vials were vortex mixed, loosely capped with Teflon-lined crimp caps and incubated at 70~ for 20 rain. Samples were then evaporated to dryness under the above conditions, dissolved in 0.2 mL ethyl acetate and transferred to vials containing inserts for gas chromatographic-mass spectrometric (GC-MS) analysis.
MET d-isomer extraction was almost identical to the AMP/MET extraction except for the omission of periodate pretreatment and the use of a derivatization procedure described elsewhere (12) . Each 2-mL urine specimen received 0.400 mL of 0.005 mg/mL AMP-dd0.005 mg/mL MET-d9 in methanol. Potassium phosphate buffer (pH 9) and sodium metaperiodate pretreatment were omitted. Instead, the specimens were buffered to pH 6 with 1.0 mL of 0.1M (pH 6) sodium phosphate buffer. After application to the Cerex column, water and acetic acid washes were I mL instead of 2 mL. The remainder of the column procedure was identical to the AMP/MET column procedure. After elution, the extracts were dried and then reconstituted with 2 mL 1-chlorobutane. Twenty microliters of TPC derivatizing reagent was added to each tube, followed by 5 tJL of triethylamine. Specimens were vortex mixed and then shaken while incubating at room temperature for 15 min. Methanol (300 I~L) was added to each specimen, then specimens were incubated for 30 min at 55-60~ Specimens were then evaporated to dryness, reconstituted with 200 lJL ethyl acetate, centrifuged at 1000-1500 rpm for 3-5 rain, and the supernatant transferred to GC autosampler vials.
Liquid-liquid extraction procedure
The steps for internal standard addition and treatment with sodium metaperiodate were the same as those described for the Cerex-Speedisk method with the exception that specimens were contained in 30-mL screw-cap tubes. Following centrifugation of the periodate-containing urine samples, 0.6 mL of 1N NaOH were added. After vortex mixing, 12 mL of dichloromethane/isopropyl alcohol (95:5, v/v) were added and the capped tubes were shaken for 15 rain at low speed. The specimens were then centrifuged for 3-5 min, the upper layer aspirated to waste and 1.3 mL of 0.2N H2SO4 added. The tubes were capped, shaken (10 rain), and centrifuged as before. The upper layer was transferred to a 13 • 100-ram tube and to this 2 drops of saturated KOH were added. The tubes were vortex mixed, 1.3 mL dichloromethane was added, and vortex mixed again for i rain. After centrifugation (3-5 rain), the upper layer was aspirated to waste, the lower layer transferred to a 2-mL autosampler vial, and to this, 0.1 mL of 1% HCl in methanol was added. SpecP mens were then evaporated to dryness and derivatized as in the Cerex-Speedisk procedure except that 0.1 mL ethyl acetate were added to each vial immediately following the addition of HFBA and prior to vortex mixing and incubation.
Periodate treatment of methamphetamine and interfering sympathomimetic amines
Aliquots of negative urine spiked with MET at a concentration of 10,000 ng/mL were contained within three separate batches that were extracted on different days. Extraction was performed using Cerex column lot 2K1031. Specimens were analyzed both with and without added internal standard. In batch 1, three different extraction conditions were tested: pH 9 with sodium metaperiodate added prior to extraction, pH 9 without periodate, and pH 6 also without periodate. Under each condition, a MET specimen and a negative QC both containing internal standard and a MET specimen with no added internal standard were extracted. Specimens extracted at pH 6 were processed by substituting I mL 0.1M sodium phosphate buffer (pH 6) for potassium phosphate buffer (pH 9) in the procedure. Non-extracted MET standards were prepared by spiking methanol to 10,000 ng/mL and then pipetting 2-mL aliquots into vials. Internal standard was added in one vial and left out of the other. These specimens were included with the urinebased extracts in the concentration step prior to derivatization. A calibration standard containing AMP, MET and internal standards AMP-d6 and MET-d9 each at 500 ng/mL in urine was extracted without periodate treatment at pH 6. In batch 2, four MET specimens of 10,000 ng/mL each in urine and a 500 ng/mL calibration standard were extracted at pH 9 subsequent to periodate treatment. In addition to the calibrator, a second specimen containing AMP and MET each at 500 ng/mL in urine was extracted at pH 9 without periodate treatment. Batch 3 contained duplicate MET specimens (10,000 ng/mL in urine) also processed at pH 9 and with periodate treatment; however, no periodate was added to the calibrator (pH 9) in this case.
Specimen mixtures of phenylpropanolamine (PPA), ephedrine and pseudoephedrine prepared by individually spiking negative urine at two concentrations, 500 ng/mL and 1 mg/mL, were extracted in duplicate in batch 2. Also extracted were duplicate specimens of pseudoephedrine spiked in negative urine at 1 mg/mL. Extraction was carried out in the presence of periodate (pH 9). A calibration standard for these specimens was prepared in methanol containing 500 ng/mL each of AMP, PPA, MET, ephedrine, and pseudoephedrine along with the same concentration of AMP-d6 and MET-d9 internal standards. In batch 3, specimen mixtures of PPA, ephedrine and pseudoephedrine each at I mg/mL in urine were extracted in duplicate subsequent to treatment with periodate. Duplicate specimens of the mixture were prepared at the concentration of 100,000 ng/mL and extracted under the same conditions. Also in batch 3 were duplicate specimens of PPA spiked at 100,000 ng/mL in both urine and methanol, the former extracted at pH 9 in the presence of periodate and the latter (non-extracted) derivatized as described previously. In this batch the calibrator was urine-based and contained 500 ng/mL each of AMP, PPA, MET, ephedrine, pseudoephedrine, and AMP-d6 and MET-d9 internal standards.
GC-MS analysis
Analysis was carried out using the Agilent GC model 5890 (series II or series II Plus) or 6890 equipped with a model G1513A autosampler interfaced with a mass selective detector (MSD) of model number 5972A or 5973N. The MSD was tuned daily using ions m/z 69, 219, and 502 of perfluorotributylamine. The GC was equipped with a DB-5MS (silphenylene polysiloxane, 12 • 0.20-mm i.d., 0.33-mm film thickness, J&W Scientific, Folsom, CA). Helium was used as the carrier gas and the linear velocity was typically 40-50 cm/s. Injection was in the split mode (1:10-1:15) using a 4-ram single taper liner (Agilent 5181-3316) that was lightly packed with silanized quartz wool. Sample injection volume was 1-2 ~L (all reported data resulting from limit of linearity [LOLl studies were obtained with a split ratio of 1:10 and a 2-~L injection volume). The injector temperature and interface temperature were held at 180~ and 300~ respectively. The initial oven temperature of 100~ (held for 1 rain) was programmed to 210~ at 15~ and immediately thereafter programmed to reach 280~ at 30~ (held for 3 rain). The program resulted in a total run time of 11 rain. The retention time (RT) for derivatized AMP was 4 rain, and the RT for MET was 5 rain. Analysis was performed in the selected ion monitoring (SIM) mode with m/z 91, 118, and 240 and m/z 123 and 244 monitored for the heptafluorobutyryl derivatives AMP and AMP-d6, respectively. Ions monitored for derivatized MET and MET-d9 were m/z 118, 210, and 254 and m/z 123 and 261, respectively. Data acquisition and analysis were performed by Agilent ChemStation Software version G1701BA or G1701CA, which generated one-point calibration data based on the peak-area ion ratios for non-deuterated drug standard versus deuterated internal standard. The ion ratio used for AMP calibration was m/z 240/244, and the ratio m/z 254/261 was used to calibrate MET.
In the study of the treatment of MET and sympathomimetic amines with sodium metaperiodate, estimated amounts PPA were obtained from a one-point calibration based on the peakarea ion ratio for m/z 240/244, and amounts of ephedrine and pseudoephedrine were estimated based on m/z 254/261 (13).
The
Acceptable analytical results were those that satisfied the following criteria: quantitative values within ,,, 20% of the theoretical value, mass ion ratios (MIRs) of qualifying ions within _ 20% of those of the calibrator, retention times within • 2% of the calibrator, baseline resolution for quantitating ion peaks, 10% valley height (relative to height of peak of interest) peak resolution for qualifying ions, and USP peak symmetry ratios between 0.5 and 1.5 at 10% of peak height.
For MET d-isomer analysis, a DB-5 column (5% phenyl)-methylpolysiloxane, 12 x 0.20-mm i.d., 0.33-pro film thickness (J&W Scientific) was used. Carrier gas, tuning, and interface temperatures were identical to those described. Initial oven temperature was 180~ held for I rain, then to 240~ at 8~
Temperature was then taken to 280~ at a rate of 30~ and held for 2 rain. Ions monitored were 251 m/z for MET and 258 m/z for MET-dg. Isomer ratios were calculated by area ratios.
Results and Discussion

Linearity
Linearity was established by analyzing four batches of individually spiked, drug-free urine standards. Two batches had concentration levels of 15, 25, 50, 100, 150, 200, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 8000, 10,000, 12,500, 15,000, and 20,000 ng/mL. Another batch contained the same levels, except for concentrations greater than 10,000 ng/mL, and one batch had levels below 50 ng/mL and above 10,000 ng/mL omitted. The assay was determined to be linear for AMP and MET to 20,000 ng/mL (m = 0.94 [r 2 = 0.9996] and m = 0.90 [r 2 = 0.9992], respectively). However, peak symmetry was out of the acceptable range for AMP at 12,500 ng/mL in both assays, and unacceptable for MET at 12,500 ng/mL in one assay and at 15,000 ng/mL in the other. The upper limit of linearity was established to be 10,000 ng/mL for both analytes~ It was noted that a shoulder appeared on the trailing edge of qualifying ion peak m/z 123 of AMP-d6 internal standard at concentrations of 5000-6000 ng/mL and increased with increases in concentration. This shoulder did not reach 10% of peak height until the AMP concentration was 20,000 ng/mL and therefore was not investigated further. Linearity curves for each analyte are shown in Figures 1 and 2 . Linear regression analysis resulted in a slope of 0.96 (r 2 = 0.9995) for AMP and 0.94 (r 2 = 0.9993) for MET. At the lower end of the concentration range, AMP and MET were quantitated within 0.5-10% of the 15-ng/mL target (15.1 ng/mL + 0.14 and 13.5 ng/mL • 0.37, respectively) but chromatographic acceptance criteria were not met. As concentrations reached 50 ng/mL MET and 150 ng/mL AMP, consistently acceptable chromatography with MIRs in range was achieved; thus, these levels were established as the lower limits of linearity for the two analytes.
A comparison of linearity between the liquid-liquid and Cerex-Speedisk methods was possible in the concentration ranges of 100-3000 ng/mL MET and 150-3000 ng/mL AMP since these are the working ranges used in our laboratory, and historical data exist for the liquid-liquid method in these ranges. Representative results for AMP and MET using the liquid-liquid method were m = 1.1 (r 2 = 0.9995) and m = 1.1 (r 2 = 0.9993), respectively. When data obtained with the Cerex-Speedisk method were analyzed using the above concentration ranges, typical results were m = 1.0 (r 2 = 0.9994) and m = 1.1 (r 2 = 0.9997) for AMP and MET, respectively. Linearity curves derived using the Cerex-Speedisk method were comparable to those obtained by using the liquid-liquid method.
Recovery
Recovery of AMP and MET from urine was determined at a concentration of 500 ng/mL for three different lots of extraction columns and also within a lot of columns at three concentrations which span the greater part of range of the assay (200, 500, and 10,000 ng/mL). Recovery experiments were performed by extracting batches consisting of spiked negative urine standards at a given concentration, a calibrator, and QC specimens. Deuterated internal standard was added to the calibrator and QC specimens prior to extraction and to the recovery standards following extraction. A one-point calibration was used to calculate the amount of recovered analyte (Table I ). For three lots of columns (between-lot precision), mean recoveries of AMP at 500 ng/mL ranged from 94.8 to 97.8% (mean + SD, 96.4% + 1.5). The values for MET at the same concentration were 93.1 to 97.9% (mean + SD, 95.7% • 2.4). Within-lot recovery data at three concentrations showed no significant difference in the amount of analyte recovered over the greater part of the range of the assay (Table I) . At 200 ng/mL, the mean recovery of AMP was 95.3% (• 1.9) and 93.4% (• 2.0) of the MET was recovered. The mean recoveries of AMP and MET at 10,000 ng/mL were 95.3% (+ 1.7) and 97.3% (• 1.4), respectively. Overall, CVs were 2.5% or less (with the maximum representing between-lot precision).
In order to compare the Cerex-Speedisk method with the liquid-liquid extraction method, a contemporaneous recovery study using the liquid-liquid method was performed. This was carried out at the cutoff concentration (500 ng/mL) with internal standard added to the recovery standards after the final transfer step in the extraction and just prior to derivatization. In this way the entire extraction process, including losses due to transfer, was reflected in the recovery results. The mean recovery of AMP was determined to be 71.3% (• 5.9, %CV 8.3) and MET was 58.5% (• 8.9, %CV 15.3). The Cerex-Speedisk method had higher recoveries of AMP and MET at the cutoff concentration as opposed to the liquid extraction with its multitransfer steps. In addition, within-batch precision was superior when using the Cerex-Speedisk method.
Precision and accuracy
Between-run precision and accuracy were determined at 50 (MET), 150 (AMP), 200, 750, 3000, 6000, and 10,000 ng/mL (Table II) . Data was obtained from batches consisting of linearity and precision standards, recovery samples, control urine blanks, and service member specimens. At the 150-ng/mL level for AMP, 4 of the 10 batches analyzed contained triplicate samples. Similarly, at 50 ng/mL MET, two of the six batches analyzed contained samples in triplicate. The between-run CV ranged from 1.7% (150 ng/mL) to 5.2% (10,000 ng/mL) in the case of AMP and from 2.4% (50 ng/mL) to 8.6% (10,000 ng/mL) for MET. Accuracy deviation over the analytical range was between -3.4 and 3.7% for AMP and between -4.6 and 3.0% for MET.
Within-run precision and accuracy were determined at 500 ng/mL for both analytes by extracting a separate batch of standards on each of three different days (Table III) . The within-run CV for each of the three batches was 1.2% or less for AMP and 1.7% or less for MET. The mean of the within-run means was 495.4 ng/mL (+ 4.9) and 496.4 ng/mL (• 3.5) for AMP and MET, respectively. Accuracy of the method at the cutoff level was within 1.9% of the target concentration for AMP and within 1.2% of the same target for MET.
Analytical results were reproducible, accurate and precise over the range of the assay and were consistent with those obtained by using the liquid-liquid extraction method for the determination of AMP and MET.
Analysis of service member specimens
Military service member specimens from our facility that tested positive for AMP and/or MET were stored frozen at-10~ • 2~ for the minimum required period of one year. These specimens were then released for experimental purposes, and 36 were extracted using both the liquid-liquid and CerexSpeedisk methods. Specimens were processed in duplicate batches of eight so that they were extracted by both methods and analyzed on the same day. Because four specimens did not contain MET at a concentration above the lower limit of linearity and because chromatographic criteria were not met for four specimens containing AMP, the number of data points for method comparison was 32 for each analyte. Specimens that contained AMP or MET at concentrations above the upper limit of linearity were diluted so that the concentration was within the range of the assay. Linear regression analysis of AMP data obtained using the two methods yielded a slope of 0.99 and r 2 of 0.9986 ( Figure 3 ). Specimen concentrations of AMP ranged from approximately 160 ng/mL to just under 20,000 ng/mL at the upper limit. The percent difference in concentration for specimens extracted by both the liquid-liquid and CerexSpeedisk methods did not exceed 8% for any specimen, and 88% of the specimens had less than a 5% difference. The concentration range for MET-containing specimens was between 500 and 600 ng/mL at the lower limit up to 40,000 ng/mL with one data point at approximately 115,000 ng/mL (diluted 10-fold). Linear regression analysis for MET gave a slope of 0.98 and an r 2 of 0.9997 (Figure 4) . Measured concentrations for MET using both methods agreed within 8%, and 88% of specimens had differences of 5% or less. There were no differences in the chromatographic profiles for AMP and MET specimens extracted by the liquid-liquid method versus the Cerex-Speedisk method. In the case of one AMP specimen that contained an interfering peak in the m/z 91 ion window, resultant chromatograms for the two methods appeared to be quite similar. Only in one instance in which several, relatively large interferences appeared throughout the TIC profile did the liquid-liquid method offer a slight improvement in chromatography; however, MIRs for AMP were out of the acceptable range. For the same specimen, the Cerex-Speedisk method resulted in AMP MIRs that were in range, but the ion peaks were too broad to be acceptable. There were no peaks in solvent blanks placed between specimens during GC-MS analysis using either method.
Effects of Cerex column extraction and sodium metaperiodate treatment on methamphetamine and other sympathomimetic amines Preliminary experiments were conducted in order to determine if conversion of MET to AMP took place upon solid-phase extraction with the Cerex column or upon oxidative pre-treatment with sodium metaperiodate (14, 15) . Specimens of 10,000 ng/mL MET in urine were extracted with and without internal standard under different conditions and trace amounts of AMP estimated (amounts were below lower LOL) from a one-point calibration curve. Methanol-based, non-extracted MET specimens (10,000 ng/mL) were also analyzed. When 10,000 ng/mL MET was extracted on three different days from urine at pH 9 with periodate treatment (and the calibration standard was extracted under the same conditions or at pH 6 without periodate), estimated amounts of AMP (N = 7) were 3-5 ng/mL (0.03-0.04% of MET). MET specimens extracted within a batch at pH 6 and 9 but with no periodate treatment (calibrator at pH 6) resulted in AMP estimates (N = 2) of 3 ng/mL (0.03% of MET). The amount of AMP estimated in non-extracted specimens of MET (N = 1) was 3 ng/mL (0.03% of MET). The trace amounts of AMP extracted from oxidized as well as non-oxidized urine-based MET specimens were consistent with the amount estimated in the original MET standard. Therefore, no conversion of MET to AMP upon treatment with periodate and subsequent solid-phase extraction was observed at the concentration tested.
The amounts of the sympathomimetic amines PPA, ephedrine and pseudoephedrine remaining after oxidation at pH 9 were also estimated for a mixture of the pure standards in urine. Mixtures of PPA, ephedrine and pseudoephedrine at two concentrations were tested: 100,000 ng/mL (urine-based calibrator) and 1 mg/mL (both urine-and methanol-based calibrators). Concentrations were determined using one-point calibration curves and were estimates since linearities for each analyte were not determined. Amounts of remaining PPA, ephedrine and pseudoephedrine varied widely. For example, at a starting concentration of I mg/mL (iV = 4) estimated PPA ranged from 6 to 480 ng/mL, ephedrine from 17 to 1050 ng/mL, and pseudoephedrine from 4 to 720 ng/mL with no apparent dependence on calibrator matrix. laboratory by liquid-liquid method. Approximately 15 mL of methylene chloride was discarded as waste with every specimen extracted. The Cerex-Speedisk method waste stream is approximately 2 mL of 50:50 methanol/ethyl acetate. The waste stream has been reduced sevenfold, and chlorinated hydrocarbon waste has been eliminated from the process. Extraction time has decreased from about 5 h for the liquid-liquid method to about 2.5 h for the Cerex-Speedisk method.
Conclusions
The current liquid-liquid partition procedure for amphetamines extraction is more labor-intensive and produces more chemical waste than the Cerex-Speedisk process. Using the Cerex-Speedisk process results in a time savings of 50%, and the reduction in chemical waste is roughly fourfold for AMP/MET, and sevenfold for MET d-isomer with complete elimination of chlorinated hydrocarbon waste in both instances. Our data show that there is neither demethylation of methamphetamine to amphetamine, nor conversion of phenylpropanolamine, ephedrine, or pseudoephedrine to AMP or MET either during periodate pretreatment of the specimen or on the Cerex resin. The resin is a modified polystyrene-divinylbenzene, that has reactive vinyl groups removed during polymerization, and that reduces the possibility of resin/drug interaction in this analysis (16) . From a time savings and a waste reduction standpoint, the Cerex-Speedisk extraction method for amphetamines is superior to the liquid-liquid analysis. Both recovery and within-batch precision are higher with the Cerex-Speedisk method, and linearity and accuracy are comparable to the liquid-liquid method. Therefore, the CerexSpeedisk method is a desirable replacement for the liquid-liquid partition method for extraction of AMP and MET from urine specimens.
